1. Meaning

Biosovereignty Doctrine is a legal and political concept concerning who has the authority to control, protect, access, use, regulate, and benefit from biological resources, human genetic information, bodily materials, and biological systems.

The doctrine connects sovereignty with biology. It raises questions about whether control over biological resources should belong to the individual, an Indigenous community, a state, or humanity collectively.

Important legal clarification: Biosovereignty is not a single, universally codified doctrine or a freestanding cause of action recognized by courts worldwide. It is best understood as an emerging analytical framework that draws upon established principles of constitutional law, privacy, bodily autonomy, public health, Indigenous rights, biodiversity law, and biotechnology regulation.

Core dimensions of biosovereignty

1. Individual biological sovereignty

A person's ability to make decisions about their body, genetic data, reproductive choices, tissues, and participation in biomedical research, subject to lawful limitations.

2. Community and Indigenous biosovereignty

Collective rights and interests concerning traditional knowledge, biological resources, cultural practices, and genetic material associated with communities.

3. State biosovereignty

A state's authority to regulate biological resources, infectious disease control, public-health emergencies, genetic research, and access to resources within its jurisdiction.

4. Global biosovereignty

The relationship between national control and international cooperation concerning biodiversity, infectious diseases, scientific research, and equitable access to biological innovations.

The central problem is balancing these interests without allowing either the state or private corporations to exercise unlimited control over biological life.

2. Historical and theoretical foundations

The doctrine develops from several established legal traditions.

Natural rights and bodily integrity: Individuals have important rights against unauthorized interference with their bodies.

Constitutional privacy: Personal autonomy and dignity can limit the collection and use of biological information.

Resource sovereignty: States exercise legally defined authority over natural resources within their territory.

Indigenous self-determination: Communities may have rights concerning their lands, traditional knowledge, and cultural heritage.

Bioethics: Informed consent, confidentiality, non-discrimination, and responsible research govern many biomedical activities.

International environmental law: Biodiversity protection and access-and-benefit-sharing rules regulate the use of genetic resources.

These traditions do not establish identical rights. For example, an individual's interest in a DNA sample is different from a state's authority over a biological resource, and neither automatically resolves who owns a patented invention developed from that resource.

3. Essential principles of the Biosovereignty Doctrine

A. Bodily autonomy and informed consent

An individual should generally be able to decide whether their biological samples, genetic information, or other personal biological material may be collected and used for research, subject to applicable law.

This principle raises several questions:

Was consent voluntary and sufficiently informed?

Was the proposed research purpose disclosed?

Can the individual withdraw from future participation?

Were commercial interests and significant risks disclosed?

Were confidentiality and genetic privacy protected?

Consent to a medical procedure does not necessarily amount to consent to every later research or commercial use of the resulting biological material.

B. Sovereign control over genetic resources

The Convention on Biological Diversity (CBD), particularly Article 15, recognizes states' sovereign rights over their natural resources and establishes a framework for access to genetic resources under national legislation. The Nagoya Protocol develops access-and-benefit-sharing rules.

United Nations Treaty Collection+1

This principle supports regulation of access to biological resources, but it does not mean that a state automatically owns every specimen, organism, or human genetic sequence located within its territory.

C. Fair and equitable benefit-sharing

When biological resources or associated traditional knowledge contribute to commercially valuable products, the applicable legal framework may require benefit-sharing arrangements.

Benefits may include:

Monetary payments or royalties.

Research partnerships and technology transfer.

Training and scientific capacity-building.

Participation in research results.

Community development or conservation benefits.

The precise obligations depend on the applicable treaty, domestic legislation, the resource involved, and the terms governing access.

D. Protection against biological exploitation

Biosovereignty provides a framework for examining situations in which researchers, corporations, or public authorities exploit biological material without adequate consent, legal authorization, or fair treatment.

Possible legal protections include privacy claims, breach of confidence, informed-consent rules, contractual remedies, biodiversity legislation, and constitutional review.

E. Accountability and proportionality

A state cannot justify every biological surveillance or control measure merely by invoking sovereignty or public health. Restrictions on individual rights must satisfy the relevant legal requirements, which may include legality, legitimate purpose, necessity, proportionality, and procedural safeguards.

This principle is especially important for genetic databases, biometric identification, biological surveillance, and compulsory medical interventions.

4. Landmark case laws

The following judgments do not all expressly use the term Biosovereignty Doctrine. They are relevant because they establish legal principles that support or limit its different dimensions.

Case 1: Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

Supreme Court of India · (2017) 10 SCC 1

Facts and issue: The case concerned whether privacy is a fundamental right under the Indian Constitution, in litigation involving the Aadhaar identification scheme.

Judgment: A nine-judge bench unanimously recognized privacy as a constitutionally protected right grounded in liberty, dignity, and personal autonomy.

PRIVACY+1

Relevance to biosovereignty:

Genetic and other biological information can reveal intimate facts about a person.

Collection and processing of such information may implicate privacy and autonomy.

State interference requires a constitutionally valid legal basis and appropriate safeguards.

Biological databases should be assessed for necessity, proportionality, purpose, and protection against misuse.

Legal significance: This is a foundational Indian constitutional authority for the individual-autonomy dimension of biosovereignty. It does not establish an unlimited right to control every use of biological material.

Case 2: Common Cause v. Union of India (2018)

Supreme Court of India · (2018) 5 SCC 1

Facts and issue: The Court considered the legality of advance medical directives and the withdrawal or withholding of life-sustaining medical treatment in specified circumstances.

Judgment: The Court recognized the right to die with dignity as part of Article 21 and established safeguards for advance directives and end-of-life decisions.

Sci API+1

Relevance to biosovereignty:

It supports personal autonomy in fundamental decisions involving the body and medical treatment.

It illustrates that bodily autonomy can operate within a regulated legal framework.

It helps explain why the state cannot treat an individual's body as an object of unrestricted governmental control.

Limitation: The judgment concerns end-of-life autonomy, not ownership of genetic data or biological resources directly.

Case 3: Moore v. Regents of the University of California (1990)

Supreme Court of California · 51 Cal. 3d 120, 793 P.2d 479

Facts: John Moore underwent treatment for leukemia. His physician used cells obtained during treatment for research without fully disclosing the research and commercial interests involved. A cell line was developed and patented.

Judgment: The California Supreme Court held that Moore could pursue claims involving breach of fiduciary duty and lack of informed consent, but rejected his conversion claim based on ownership of the excised cells.

Justia Law+1

Legal principles:

A physician must disclose material research or financial interests that may affect medical judgment.

Consent to treatment does not automatically resolve questions about undisclosed research.

The law may distinguish between biological material removed from a person's body and a patented cell line developed from it.

Relevance to biosovereignty: The case exposes the conflict between individual control over biological material, commercial biotechnology, and scientific research.

Critical limitation: The decision did not recognize comprehensive property ownership over all biological material. It is particularly important as an example of how informed-consent rights may protect a patient even when a proprietary claim fails.

Case 4: Navtej Singh Johar v. Union of India (2018)

Supreme Court of India · (2018) 10 SCC 1

Facts and issue: The Court examined the constitutionality of criminalizing consensual same-sex intimacy between adults under Section 377 of the Indian Penal Code, to the extent applicable to such conduct.

Judgment: The Court decriminalized consensual same-sex relations between adults, emphasizing dignity, privacy, equality, and personal autonomy.

Sci API+1

Relevance to biosovereignty: Although not a biotechnology case, it reinforces the principle that intimate personal decisions cannot be controlled arbitrarily by the state merely because they concern sexuality or personal identity.

Its relevance is strongest when biosovereignty arguments concern reproductive autonomy, genetic discrimination, or state interference with intimate bodily decisions.

Case 5: Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

Supreme Court of the United States · 569 U.S. 576

Issue: Whether naturally occurring human DNA isolated from the body could be patented merely because it had been isolated.

Judgment: The Court held that naturally occurring DNA segments are not patent-eligible merely because they have been isolated, while synthetically created complementary DNA (cDNA) may be patent-eligible, subject to the Court's stated distinction and applicable patent law.

Relevance to biosovereignty:

Human genetic information raises questions different from ordinary commercial property.

Scientific discoveries involving nature do not automatically become patentable inventions.

Patent rights over biotechnology do not, by themselves, settle the question of who may collect or use a person's biological samples.

Limitation: This is a patent-eligibility decision, not a general ruling that individuals or states own human DNA.

Case 6: Diamond v. Chakrabarty (1980)

Supreme Court of the United States · 447 U.S. 303

Facts: An inventor sought a patent for a genetically engineered bacterium capable of breaking down components of crude oil.

Judgment: The Court held that the engineered microorganism fell within the relevant US patent statute's subject matter because it was a human-made invention rather than a naturally occurring organism.

Relevance to biosovereignty: The case illustrates the difference between regulating access to biological resources and granting intellectual property rights over qualifying inventions developed using them.

Limitation: Patent eligibility does not independently determine whether the underlying biological material was lawfully obtained, whether consent was required, or whether benefit-sharing obligations apply.

Case 7: S. and Marper v. United Kingdom (2008)

European Court of Human Rights · Applications Nos. 30562/04 and 30566/04

Facts: The applicants challenged the indefinite retention of fingerprints, cellular samples, and DNA profiles after criminal proceedings against them had ended without conviction.

Judgment: The Grand Chamber found a violation of Article 8 of the European Convention on Human Rights, concerning respect for private life and family life.

Relevance to biosovereignty:

Biological samples and genetic profiles can implicate privacy even when collected by law enforcement.

Government possession of biological data requires safeguards against indiscriminate retention and misuse.

The distinction between physical samples and derived genetic information matters for privacy analysis.

Limitation: The judgment interprets the European Convention and does not automatically determine the law in India or other jurisdictions.

Case 8: Greenpeace Nordic Association v. Norway (2025)

This environmental and climate-law judgment is sometimes relevant to broader sovereignty discussions, but it does not directly establish a biosovereignty doctrine. For a focused analysis, the stronger authorities remain the constitutional privacy cases and the biodiversity access-and-benefit-sharing framework.

5. International legal framework

The doctrine's international dimension is supported by the following instruments.

The CBD and Nagoya Protocol are particularly important for state and community biosovereignty. The ICCPR and Indigenous rights framework provide complementary protections for privacy, cultural interests, and self-determination. Their application depends on the relevant treaty obligations and domestic law.

United Nations Treaty Collection+2

Prior informed consent and mutually agreed terms

Two concepts are particularly important:

Prior informed consent (PIC): Authorization required under the applicable legal regime before access to certain genetic resources or associated knowledge.

Mutually agreed terms (MAT): Agreed conditions governing access and use, which may include benefit-sharing and restrictions on transfer or commercialization.

These concepts do not mean that every biological sample everywhere is subject to identical consent procedures. The resource's nature, the provider, applicable legislation, and any relevant exceptions all matter.

6. Biosovereignty Doctrine under Indian law

India does not have one statute that comprehensively codifies a general Biosovereignty Doctrine. Instead, the doctrine's components can be examined through constitutional rights, biodiversity legislation, biomedical research regulation, and data protection law.

A. Constitutional provisions

Articles 21, 48A and 51A(g), read with the applicable statutory framework, can inform disputes involving bodily autonomy, biological information, biodiversity, and environmental protection.

B. Biological Diversity Act, 2002

India's Biological Diversity Act establishes a regulatory framework for biological resources and associated traditional knowledge, including access, conservation, and benefit-sharing.

Its importance for biosovereignty includes:

Regulating access to biological resources in circumstances covered by the Act.

Protecting relevant interests in associated traditional knowledge.

Providing mechanisms for equitable sharing of benefits.

Supporting conservation and sustainable use of biodiversity.

The Act must be read with its applicable amendments, rules, and current administrative requirements. It is not a blanket declaration that the Indian government owns every biological resource or all human genetic material.

C. Digital Personal Data Protection Act, 2023

Genetic information and other biological data may fall within the personal-data framework when they qualify as digital personal data under the Act. The precise application depends on the data, processing activity, and applicable provisions and exemptions.

This legislation is relevant to biosovereignty because digital genetic records can be stored, transferred, analyzed, and used for purposes beyond their original collection. Data protection, however, is not equivalent to ownership of the underlying biological sample.

D. Biomedical research and informed consent

Research involving human participants is also governed by applicable biomedical research requirements, including relevant ethics committee review, informed-consent standards, and institutional safeguards.

A biosovereignty analysis should therefore distinguish between:

Human biological specimens.

Identifiable genetic information.

Anonymized or de-identified research data.

Traditional knowledge associated with biological resources.

Inventions and patented products derived from biological research.

Different legal rules can apply to each category.

7. Practical applications of the doctrine

Scenario 1: Commercial use of donated tissue

A hospital obtains a patient's tissue for diagnosis and later uses it for unrelated commercial research without adequate disclosure.

Legal analysis: Examine informed consent, professional duties, research ethics, confidentiality, and applicable statutory rules. Moore is a useful comparative authority.

Scenario 2: Genetic surveillance by the state

A government agency builds a DNA database for law-enforcement purposes.

Legal analysis: Assess statutory authority, legitimate purpose, necessity, proportionality, data security, retention periods, and avenues for challenging misuse. Puttaswamy and S. and Marper provide relevant principles.

Scenario 3: Commercial exploitation of traditional medicinal knowledge

A company uses a community's traditional biological knowledge to develop a commercial product.

Legal analysis: Determine whether applicable biodiversity legislation, access-and-benefit-sharing rules, traditional-knowledge protections, or contractual obligations require authorization or benefit-sharing.

Scenario 4: Emergency pathogen sharing

A country restricts access to biological samples collected during an infectious-disease outbreak.

Legal analysis: Consider domestic public-health authority, international cooperation, applicable pathogen-sharing arrangements, research ethics, and equitable access to resulting diagnostics, vaccines, or treatments. State sovereignty must be evaluated alongside relevant international obligations.

8. Accountability and constitutional limits

A defensible biosovereignty framework should apply the following safeguards:

Legality: Biological collection, surveillance, or restriction must have an appropriate legal basis.

Legitimate purpose: The measure must pursue a legally permissible objective, such as public health or biodiversity conservation.

Necessity and proportionality: The interference should be justified and no broader than reasonably required under the applicable legal test.

Informed consent: Obtain valid consent where required, and disclose material risks and research or commercial purposes.

Transparency: Explain how biological materials and data will be used, shared, retained, and protected.

Fair benefit-sharing: Respect applicable rights and obligations involving biological resources and traditional knowledge.

Non-discrimination: Avoid unjustified discrimination based on genetic characteristics or biological classifications.

Effective remedies: Provide appropriate mechanisms for complaints, judicial review, compensation, and correction of unlawful practices.

These safeguards are especially important because biological information can affect not only an individual but also relatives, communities, and future generations.

9. Critical evaluation

The Biosovereignty Doctrine presents three major legal tensions.

First, individual autonomy versus public health. People have important interests in bodily integrity and privacy, but lawful public-health measures may sometimes justify restrictions. The legality and proportionality of each measure must be assessed.

Second, state sovereignty versus global scientific cooperation. States may regulate access to genetic resources, but excessive restrictions can impede research, disease surveillance, and the equitable distribution of scientific benefits.

Third, community rights versus private intellectual property. A company may hold rights over a qualifying invention without necessarily acquiring unrestricted rights over the source material, associated traditional knowledge, or the community from which it originated.

The doctrine's principal value is that it encourages courts, lawmakers, and regulators to consider these competing interests together rather than treating biological resources solely as commodities, private property, or instruments of state power.

10. Conclusion

The Biosovereignty Doctrine is best understood as a composite legal framework for biological autonomy, resource governance, privacy, community rights, and accountable state authority.

Its strongest existing legal foundations are:

Justice K.S. Puttaswamy v. Union of India (2017) — constitutional privacy and autonomy.

Common Cause v. Union of India (2018) — bodily and medical decision-making autonomy.

Moore v. Regents of the University of California (1990) — informed consent and commercial use of human tissue.

Diamond v. Chakrabarty (1980) — patent eligibility for a human-engineered microorganism.

Association for Molecular Pathology v. Myriad Genetics, Inc. (2013) — limits on patenting naturally occurring DNA.

S. and Marper v. United Kingdom (2008) — privacy protection against disproportionate retention of DNA samples and profiles.

Together, these authorities demonstrate that biological governance involves multiple legal interests. They do not, however, establish a universal rule that individuals, communities, or states possess absolute ownership or control over all biological materials.

Educational note: This is a comparative legal overview, not legal advice for a particular dispute. For litigation or research in India, the applicable statutory provisions, current amendments, and precise facts should be checked before relying on any proposition.